Company Description
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company.
Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 168 |
| CEO | Dr. Robert Ang M.B.A., M.D., MBBS |
Contact Details
Address: 100 Cambridgepark Drive, Suite 101 Cambridge, Massachusetts 02140 United States | |
| Phone | 617-655-6580 |
| Website | vorbio.com |
Stock Details
| Ticker Symbol | VOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001817229 |
| CUSIP Number | 929033108 |
| ISIN Number | US9290331084 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Ang M.B.A., M.D., MBBS | President, Chief Executive Officer and Director |
| Tania Philipp | Chief People Officer |
| Dr. Robert G. Pietrusko Pharm. D., Pharm.D. | Chief Regulatory Officer |
| John C. King M.B.A. | Chief Commercial Officer |
| Dr. Eyal C. Attar M.D. | Chief Medical Officer |
| Samir Vattompadam M.S. | Senior Vice President of Portfolio Strategy and Program Management |
| David Phillips M.B.A. | Senior Vice President and Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | ARS | Filing |
| Apr 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2024 | 10-K | Annual Report |
| Feb 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 5, 2024 | 8-K | Current Report |
| Nov 7, 2023 | 10-Q | Quarterly Report |